Avalon and Orange, Calif. — UCI Health and Catalina Island Medical Center are pleased to announce a clinical affiliation between the University of California, Irvine’s leading academic health system and Catalina Island’s primary …
Read More
News
The recent FDA approval of lecanemab has generated a lot of buzz in recent days and UCI MIND director, Joshua Grill, PhD has been asked to comment in various highly visible media outlets including the Washington Post and today, in National Geographic. …
UCI MIND faculty member and professor, Mathew Blurton-Jones, PhD, is featured in AlzForum for his lab’s recent collaborative work on creating a new strain of resistant microglia. Lead author and graduate student in the Blurton-Jones lab, Jean Paul Chadarevian, along with collaborators at the University of Pennsylvania published their innovative work in Journal of Experimental Medicine in the December 2022 issue. Read the full article here >
The post Healthy, Drug-Resistant Microglia Reinvigorate Mouse Brain appeared first on UCI MIND.
The post FDA grants accelerated approval to lecanemab appeared first on UCI MIND.
UCI Health is home to over 190 doctors who have been named 2023 Physicians of Excellence by the Orange County Medical Association (OCMA), more than any other hospital in the region.
OCMA’s Physician of Excellence program, now in its 19th year, is regar…
UCI MIND Faculty Member Elizabeth Head, PhD was featured in the Akron Beacon Journal: I recently interviewed Dr. Elizabeth Head, a [professor and] neuropathology core co-investigator at the Alzheimer’s Disease Research Center at University of California, Irvine. While she collaborates with researchers studying Alzheimer’s in the general population, her research is focused specifically on the Down syndrome population. Her team and others are conducting longitudinal studies, in which volunteers with Down syndrome participate for many years, discovering relevant data that are the building blocks for future treatments. Read the full article here >
The post Alzheimer’s research in people with Down syndrome benefits all appeared first on UCI MIND.
Irvine, Calif. — UC Irvine researchers have developed and successfully tested a new data exchange system to provide first responders with real-time, critical health information about senior care center residents, who are at greatest risk during d…
Orange, Calif. – UCI Health is proud to announce it has been named a 2022 Climate Champion by Health Care Without Harm. The Climate Champion Awards recognize healthcare organizations for their progress and commitment to reducing greenhouse gas em…
The work of our faculty, researchers, and collaborators was highlighted in a recent Alzforum article on anti-tau vaccines. AC Immune updates Phase 1b/2 comparison of two anti-#tau vaccines. A liposomal vaccine prompted #antibody response against phospho-tau. Preclinical data bode well for another tau vaccine; first trial slated for next year. Read more >
The post Two New Stabs at Vaccinating People Against Pathologic Tau appeared first on UCI MIND.
IN THE NEWS: A Texas college student returned to Orange County to thank the UCI Health burn and trauma teams for saving his life after a fiery car crash last December took both his legs below the knee and left him severely burned.
Calling the trip…
UCI MIND Director Joshua Grill, PhD is featured in and comments on Alzforum’s report on “convincing and noteworthy” lecanemab results. The slightly larger effect on [activities of daily living] ADLs caught the interest of some scientists, since these can feel most important to participants. “[This] indicates that patients and families could benefit from slowing of observable functional worsening,” Joshua Grill of the University of California, Irvine, wrote to Alzforum (full comments below). Read his commentary here > Read the full article here >
The post Dare We Say Consensus Achieved: Lecanemab Slows the Disease appeared first on UCI MIND.
Orange, Calif. – UCI Health has been named a Conservation Champion by the water efficiency group Water Savers Solutions (WSS).
The academic health system continues to be at the forefront of water-saving efficiencies and conservation, making sign…
Message from the Director Dear Friends of UCI MIND, As the fall MIND Matters newsletter goes to print, many of us are preparing to travel to San Francisco for the annual Clinical Trials in Alzheimer’s Disease (CTAD) meeting, where we will hear important results from recently completed Phase 3 clinical trials of potential new therapies for Alzheimer’s disease (AD). This includes trials of lecanemab (page 1) as well as other treatments. The topline results for lecanemab announced by the trial sponsors are exciting and suggest that lecanemab may slow the progression of AD. The availability of treatments to slow the…
The post MIND Matters | Quarterly Newsletter | Fall 2022 appeared first on UCI MIND.
IN THE NEWS: Patients who choose conservative management for advanced kidney disease have lower hospitalization rates than patients who opt for dialysis, according to a study presented at the American Society for Nephrology’s annual conferenc…
Orange, Calif. – UCI Health today was again named one of the nation’s the best hospitals for maternity care for 2022-23, earning a “high-performing” rating, the highest available, by U.S. News & World Report.
It is the second year …
Eat This, Not That! “According to a study performed by UCI MIND and presented at the American Association for the Advancement of Science, there’s a connection between longevity and drinking a moderate amount of alcohol. (Let’s stress …
When the U.S. Food and Drug Administration gave controversial accelerated approval to the first Alzheimer’s drug in nearly 20 years, it had a surprising impact on attitudes about research into the disease. A survey by University of California, Irvine neuroscientists has found news coverage of the FDA’s decision made the public less willing to volunteer for Alzheimer’s pharmaceutical trials. The study was conducted by the UCI Institute for Memory Impairments and Neurological Disorders, known as UCI MIND. It appears in the Journal of Alzheimer’s Disease. (Link to abstract) The UCI team performed the survey in tandem with the FDA’s spring…
The post Controversial Alzheimer’s drug approval sparks surprising impact appeared first on UCI MIND.
Contributed by Joshua Grill, PhD On the opening night of the Clinical Trials for Alzheimer’s Disease (CTAD) meeting, a packed room was abuzz with excitement. The evening included five presentations related to the Phase 3 CLARITY-AD trial of lecanemab, a monoclonal antibody against the beta amyloid protein that builds up in the brain of a person with Alzheimer’s disease. The excitement and anticipation were palpable, since the sponsor of the trial, Eisai, had announced in September that the results were positive. The presentations were accompanied by the full publication of the results in the New England Journal of Medicine and coverage…
The post CTAD Abuzz appeared first on UCI MIND.
Contributed by Joshua Grill, PhD and David Sultzer, MD An article in ScienceInsider, a news outlet published by Science magazine, reports on an unpublished case of a person who died after treatment with the monoclonal antibody lecanemab. Lecanemab is a promising investigational treatment, seemingly poised for FDA approval as a disease-modifying treatment for Alzheimer’s disease. Topline results were announced in September that indicated lecanemab had been shown to slow progression of disease. The full data will be presented tomorrow at the Clinical Trials in Alzheimer’s Disease (CTAD) international conference. The presentation should include efficacy as well as safety data for lecanemab. As…
The post Are there new safety concerns for Lecanemab? appeared first on UCI MIND.
Irvine, Calif. – UCI Health and UCI Alpha Clinic have launched the first U.S. clinical trial to test the safety and tolerability of IMM01-STEM in patients with knee osteoarthritis to prevent muscle atrophy.
Up to 18 patients ranging in age from …